6533b7dafe1ef96bd126d9b7

RESEARCH PRODUCT

Recurrence of hepatocellular carcinoma after liver transplantation: an update.

Tommaso Vincenzo BartolottaRodolfo SaccoSalvatore PettaAlessandra MazzolaAlessandra MazzolaCalogero CammàSanti Maurizio RaineriAndrea CostantinoGiuseppe BrancatelliGiuseppe Cabibbo

subject

SorafenibOncologyCancer Researchmedicine.medical_specialtyrecurrenceCarcinoma Hepatocellularmedicine.medical_treatmentliving donorLiver transplantationMilan criteriaGastroenterologyLeukocyte CountRisk FactorsInternal medicinemedicineBiomarkers TumorCombined Modality TherapyHumansalpha-FetoproteinPerioperative PeriodSurvival rateimmunosuppressionbusiness.industryRisk FactorLiver NeoplasmsImmunosuppressionGeneral MedicinePerioperativehepatocellular carcinomamedicine.diseaseCombined Modality Therapydigestive system diseasesLiver TransplantationTumor BurdenOncologyLiver NeoplasmHepatocellular carcinomaalpha-FetoproteinsNeoplasm Recurrence Localbusinessmedicine.drugHuman

description

Liver transplantation is the only curative alternative for selected patients with hepatocellular carcinoma (HCC) who are not eligible for resection and/or with decompensated cirrhosis. According to Milan criteria the 5-year survival rate is 70–85%, with a recurrence-free survival of 75%. However, HCC recurrence rate after liver transplantation remains a significant problem in the clinical practice. The prognosis in patients with HCC recurrence is poor. The treatment of choice for HCC recurrence is surgery, but it seems that a systemic treatment based on combination of an mTOR inhibitor with sorafenib can be used. Data on safety and efficacy are limited, clinical monitoring is necessary. The aim of this review is to underline the main concerns, pitfalls and warnings for these patients.

yearjournalcountryeditionlanguage
2015-11-01Future oncology (London, England)
10.2217/fon.15.239https://pubmed.ncbi.nlm.nih.gov/26414336